MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Price & Overview

TSX:MBX • CA59501P1045

Current stock price

0.25 CAD
+0.01 (+2.04%)
Last:

The current stock price of MBX.CA is 0.25 CAD. Today MBX.CA is up by 2.04%. In the past month the price increased by 6.38%. In the past year, price decreased by -39.02%.

MBX.CA Key Statistics

52-Week Range0.21 - 0.45
Current MBX.CA stock price positioned within its 52-week range.
1-Month Range0.225 - 0.26
Current MBX.CA stock price positioned within its 1-month range.
Market Cap
34.638M
P/E
N/A
Fwd P/E
3.54
EPS (TTM)
-0.03
Dividend Yield
N/A

MBX.CA Stock Performance

Today
+2.04%
1 Week
-3.85%
1 Month
+6.38%
3 Months
+16.28%
Longer-term
6 Months N/A
1 Year -39.02%
2 Years -31.51%
3 Years -34.21%
5 Years -57.63%
10 Years -10.71%

MBX.CA Stock Chart

MICROBIX BIOSYSTEMS INC / MBX Daily stock chart

MBX.CA Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to MBX.CA. When comparing the yearly performance of all stocks, MBX.CA is a bad performer in the overall market: 87.37% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

MBX.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to MBX.CA. While MBX.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MBX.CA Earnings

Next Earnings DateMay 13, 2026
Last Earnings DateFeb 12, 2026
PeriodQ1 / 2026
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

MBX.CA Forecast & Estimates

5 analysts have analysed MBX.CA and the average price target is 0.51 CAD. This implies a price increase of 104% is expected in the next year compared to the current price of 0.25.

For the next year, analysts expect an EPS growth of 33.33% and a revenue growth 35.93% for MBX.CA


Analysts
Analysts80
Price Target0.51 (104%)
EPS Next Y33.33%
Revenue Next Year35.93%

MBX.CA Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

MBX.CA Financial Highlights

Over the last trailing twelve months MBX.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by -320.71% compared to the year before.


Income Statements
Revenue(TTM)16.76M
Net Income(TTM)-4.27M
Industry RankSector Rank
PM (TTM) N/A
ROA -11.67%
ROE -16.05%
Debt/Equity 0.25
Chartmill High Growth Momentum
EPS Q2Q%-233.33%
Sales Q2Q%-30.2%
EPS 1Y (TTM)-320.71%
Revenue 1Y (TTM)-27.23%

MBX.CA Ownership

Ownership
Inst Owners0.43%
Shares138.55M
Float117.23M
Ins Owners14.85%
Short Float %N/A
Short RatioN/A

About MBX.CA

Company Profile

MBX logo image Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm develops and commercializes proprietary biological and technology solutions for human health and wellbeing. The company manufactures a range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment and proficiency testing controls (QAPsTM business), and sample collection devices (DxTMTM business). The firm operates in two ways: (i) the development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples, and (ii) the development and commercialization of novel and proprietary products or technologies such as Kinlytic. It's Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots.

Company Info

IPO: 1992-10-01

MICROBIX BIOSYSTEMS INC

265 Watline Avenue

Mississauga ONTARIO L4Z 1P3 CA

CEO: Cameron Groome

Employees: 0

MBX Company Website

MBX Investor Relations

Phone: 19053618910

MICROBIX BIOSYSTEMS INC / MBX.CA FAQ

What does MICROBIX BIOSYSTEMS INC do?

Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm develops and commercializes proprietary biological and technology solutions for human health and wellbeing. The company manufactures a range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment and proficiency testing controls (QAPsTM business), and sample collection devices (DxTMTM business). The firm operates in two ways: (i) the development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples, and (ii) the development and commercialization of novel and proprietary products or technologies such as Kinlytic. It's Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots.


What is the stock price of MICROBIX BIOSYSTEMS INC today?

The current stock price of MBX.CA is 0.25 CAD. The price increased by 2.04% in the last trading session.


Does MBX stock pay dividends?

MBX.CA does not pay a dividend.


What is the ChartMill rating of MICROBIX BIOSYSTEMS INC stock?

MBX.CA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Can you provide the sector and industry classification for MICROBIX BIOSYSTEMS INC?

MICROBIX BIOSYSTEMS INC (MBX.CA) operates in the Health Care sector and the Biotechnology industry.


What is the market capitalization of MBX stock?

MICROBIX BIOSYSTEMS INC (MBX.CA) has a market capitalization of 34.64M CAD. This makes MBX.CA a Nano Cap stock.


Can you provide the upcoming earnings date for MICROBIX BIOSYSTEMS INC?

MICROBIX BIOSYSTEMS INC (MBX.CA) will report earnings on 2026-05-13.